William Hill price target lowered to 272 GBp from 300 GBp at RBC Capital » 12:5910/2710/27/20
RBC Capital analyst…
RBC Capital analyst Christine Zhou lowered the firm's price target on William Hill to 272 GBp from 300 GBp and keeps a Sector Perform rating on the shares.
Intrado to divest Health Advocate business for $690M to Teleperformance » 12:4710/2710/27/20
Intrado announced it has…
Intrado announced it has entered into a definitive agreement with Teleperformance, a global group in digitally integrated business services, for the sale of Intrado's Health Advocate business for the purchase price of $690M. "After a strategic review of our businesses, we made the decision to sell Health Advocate to allow greater focus on Intrado's other cloud businesses," said John Shlonsky, President and CEO of Intrado. "Teleperformance will be an outstanding home for Health Advocate. Teleperformance's focus on personalized customer experience and innovation aligns closely with Health Advocate's nearly identical priorities. We are excited for the Health Advocate team to be able to continue to expand the business within the world-class Teleperformance organization." The transaction is expected to close in the first quarter of 2021, subject to regulatory approvals and other customary closing conditions. Intrado is controlled by affiliates of certain funds managed by Apollo Global Management.
JPMorgan gaming analyst to hold an analyst/industry conference call » 09:4010/2710/27/20
US Gaming & Lodging…
US Gaming & Lodging Analyst Politzer and EMEA Special Situations Analyst Dunlop discuss Caesars Entertainment and William Hill signing their first NFL team sponsorship, becoming a sports betting partner of the Indianapolis Colts on an Analyst/Industry conference call to be held on October 27 at 10 am.
Novavax expects interim data from Phase 3 COVID-19 trial as soon as 1Q21 » 09:0510/2710/27/20
Novavax announced updates…
Novavax announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX-CoV2373 is a stable, prefusion protein made using Novavax' nanoparticle technology and includes Novavax' proprietary Matrix-M adjuvant. The Company also announced that it will present data from its ongoing Phase 1/2 clinical trial, including new Phase 2 reactogenicity data, on Friday, October 30 during the United States Center for Disease Control and Prevention's Advisory Committee on Immunization Practices' meeting. Novavax has enrolled over 5,500 participants to date in the United Kingdom trial, which it has expanded to 15,000 volunteers. The increased enrollment is likely to facilitate assessment of safety and efficacy in a shorter time period. Novavax expects this trial to be fully enrolled by the end of November, and dependent on the overall COVID-19 attack rate, interim data in this event-driven trial are expected as soon as early first quarter 2021. These data are expected to serve as the basis for global licensure. Novavax currently expects the pivotal clinical trial to begin in the United States and Mexico by the end of November. The Company has made significant progress in large-scale manufacturing, with delays experienced versus original timing estimates. Novavax has been developing large-scale manufacturing processes at multiple sites around the world and plans to use production from its contract manufacturing site at FUJIFILM Diosynth Biotechnologies' Morrisville, North Carolina site in this Phase 3 clinical trial. Novavax' first pivotal Phase 3 clinical trial, begun in September in partnership with the U.K. Government's Vaccines Taskforce, will be expanded from 10,000 to 15,000 volunteers, some of whom have been recruited through the National Health Service Vaccine Registry. The trial protocol calls for unblinding of data once 152 participants have achieved mild, moderate or severe endpoints. Two interim analyses are planned once 66 and 110 endpoints have occurred. Novavax' pivotal Phase 3 clinical trial is being conducted with support from the U.S. Government through Operation Warp Speed. The trial design is harmonized with those of other leading companies, and calls for the enrollment of up to 30,000 participants in the U.S. and Mexico, with proportional representation among diverse populations most vulnerable to COVID-19 distributed across race/ethnicity, age and those living with co-morbidities. The trial protocol will be posted on Novavax' website upon initiation.
DraftKings extends sports betting agreement with MansionBet » 06:1010/2710/27/20
DraftKings announced the…
DraftKings announced the renewal and extension of its relationship with MansionBet, the Gibraltar based sport betting brand of the Mansion Group, a leading provider of online gaming, with a portfolio of well-known online casino brands, as well as a sportsbook. The long-term agreement will see DraftKings' B2B technology continue to power the tier one operator's sportsbook and casino platform, in addition to providing a suite of managed services covering compliance, payments and anti-fraud protocols. Having experienced significant growth since launching in 2018, MansionBet will now leverage DraftKings' suite of APIs across their entire sportsbook. The expansion will significantly enhance MansionBet's customer offerings and experience, particularly for horse racing, which will now feature additional streaming coverage and Timeform content from both U.K. and international tracks.
Novavax down 6% to $87.41 in late afternoon trading » 15:4610/2610/26/20
Rumors about delays for a…
Rumors about delays for a trial of the COVID-19 vaccine being developed by Novavax have been pointed to as a possible reason for the stock's weakness, according to trading contacts.
Apollo Global upgraded to Outperform from In Line at Evercore ISI » 06:3410/2610/26/20
Evercore ISI analyst…
Evercore ISI analyst Glenn Schorr upgraded Apollo Global to Outperform from In Line with a $52 price target.
Bet On It: Pennsylvania a battleground state for sportsbooks » 07:0510/2510/25/20
CZR, LVS, DKNG, PDYPY, MGM, PENN
Welcome to The Fly's…
Friday Parlay: Pennsylvania a battleground state for sportsbooks » 16:0410/2310/23/20
CZR, LVS, DKNG, PDYPY, MGM, PENN
Welcome to The Fly's…
Aksia, CT treasurer halt new investments with Apollo, Bloomberg says » 14:2810/2310/23/20
Aksia has told its…
Aksia has told its clients to not give new money to Apollo Global Management amid lingering questions about the relationship between Apollo's co-founder Leon Black and Jeffrey Epstein, reported Bloomberg's Gillian Tan, citing an Aksia client communication. Meanwhile, Gabrielle Farrell, a spokeswoman for Connecticut's State Treasurer Shawn Wooden, said in an emailed statement to Bloomberg: "The existing Apollo commitments were made under the previous administration and we have no plans to commit further capital to their funds at this time."